Edge Capital Group LLC Purchases 11,284 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Edge Capital Group LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 622.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 13,096 shares of the medical research company’s stock after buying an additional 11,284 shares during the quarter. Edge Capital Group LLC’s holdings in IQVIA were worth $2,573,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. South Dakota Investment Council bought a new stake in shares of IQVIA in the 4th quarter worth approximately $2,462,000. Howard Capital Management Inc. raised its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the period. Abound Financial LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $512,000. Invera Wealth Advisors LLC raised its holdings in shares of IQVIA by 0.7% in the 4th quarter. Invera Wealth Advisors LLC now owns 14,098 shares of the medical research company’s stock worth $2,904,000 after purchasing an additional 102 shares during the period. Finally, Cumberland Partners Ltd raised its holdings in shares of IQVIA by 6.0% in the 4th quarter. Cumberland Partners Ltd now owns 1,759 shares of the medical research company’s stock worth $346,000 after purchasing an additional 99 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $251.22.

Insiders Place Their Bets

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ? increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $190.94 on Monday. The company has a market cap of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a 50-day moving average of $199.57 and a 200 day moving average of $216.25.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.